•
Apr 30, 2020

Cooper Q2 2020 Earnings Report

CooperCompanies' financial performance declined due to the impact of the COVID-19 pandemic.

Key Takeaways

CooperCompanies reported a 20% decrease in revenue to $524.9 million, with GAAP diluted earnings per share down 91% to $0.23 and non-GAAP diluted earnings per share down 48% to $1.51 compared to the same quarter last year. The company experienced a decrease in revenue for both CooperVision and CooperSurgical segments.

Revenue decreased 20% year-over-year to $524.9 million.

CooperVision (CVI) revenue was down 17% to $402.2 million.

CooperSurgical (CSI) revenue was down 28% to $122.7 million.

GAAP diluted earnings per share decreased to $0.23, a 91% decrease year-over-year.

Total Revenue
$525M
Previous year: $654M
-19.8%
EPS
$0.38
Previous year: $0.74
-48.6%
Gross margin
62%
Previous year: 66%
-6.1%
Operating margin
5%
Previous year: 22%
-77.3%
Gross Profit
$324M
Previous year: $433M
-25.2%
Cash and Equivalents
$79.8M
Previous year: $105M
-23.7%
Free Cash Flow
-$63.5M
Previous year: $162M
-139.2%
Total Assets
$6.51B
Previous year: $6.2B
+4.9%

Cooper

Cooper

Cooper Revenue by Segment

Cooper Revenue by Geographic Location

Forward Guidance

Given the uncertainty on near-term financial results caused by the COVID-19 pandemic, the company is no longer providing fiscal year 2020 guidance.

Revenue & Expenses

Visualization of income flow from segment revenue to net income